161 related articles for article (PubMed ID: 33564657)
1. Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases - Is It Time to Update the EU's Orphan Regulation? And if so, What Should be Changed?
Horgan D; Moss B; Boccia S; Genuardi M; Gajewski M; Capurso G; Fenaux P; Gulbis B; Pellegrini M; Mañú Pereira MDM; Gutiérrez Valle V; Gutiérrez Ibarluzea I; Kent A; Cattaneo I; Jagielska B; Belina I; Tumiene B; Ward A; Papaluca M
Biomed Hub; 2020; 5(2):1-11. PubMed ID: 33564657
[TBL] [Abstract][Full Text] [Related]
2. Orphan Medicines for Pediatric Use: A Focus on the European Union.
Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
[TBL] [Abstract][Full Text] [Related]
3. Tackling rare diseases at European level: why do we need a harmonized framework?
Taruscio D; Trama A; Stefanov R
Folia Med (Plovdiv); 2007; 49(1-2):59-67. PubMed ID: 18018471
[TBL] [Abstract][Full Text] [Related]
4. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
5. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
6. A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries.
Czech M; Baran-Kooiker A; Atikeler K; Demirtshyan M; Gaitova K; Holownia-Voloskova M; Turcu-Stiolica A; Kooiker C; Piniazhko O; Konstandyan N; Zalis'ka O; Sykut-Cegielska J
Front Public Health; 2019; 7():416. PubMed ID: 32117845
[No Abstract] [Full Text] [Related]
7. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
[TBL] [Abstract][Full Text] [Related]
8. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
9. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
10. Delayed access to treatments for rare diseases: who's to blame?
Feltmate K; Janiszewski PM; Gingerich S; Cloutier M
Respirology; 2015 Apr; 20(3):361-9. PubMed ID: 25722183
[TBL] [Abstract][Full Text] [Related]
11. Cooperating on Data: The Missing Element in Bringing Real Innovation to Europe's Healthcare Systems.
Horgan D; Bernini C; Thomas PPM; Morre SA
Public Health Genomics; 2019; 22(3-4):77-101. PubMed ID: 31634895
[TBL] [Abstract][Full Text] [Related]
12. The EU as a Political Determinant of Global Health: The Case of Research and Development Incentives for Orphan Medicines and Biotechnology.
Perehudoff K; Ippel KA
J Health Polit Policy Law; 2024 Apr; ():. PubMed ID: 38567770
[TBL] [Abstract][Full Text] [Related]
13. Review of 11 national policies for rare diseases in the context of key patient needs.
Dharssi S; Wong-Rieger D; Harold M; Terry S
Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
[TBL] [Abstract][Full Text] [Related]
14. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.
Song P; Gao J; Inagaki Y; Kokudo N; Tang W
Intractable Rare Dis Res; 2012 Feb; 1(1):3-9. PubMed ID: 25343064
[TBL] [Abstract][Full Text] [Related]
15. Propelling Health Care into the Twenties.
Horgan D; Borisch B; Richer E; Bernini C; Kalra D; Lawler M; Ciliberto G; Van Poppel H; Paradiso A; Riegman P; Triberti S; Metspalu A; Chiti A; Macintyre E; Boccia S; Calvo F; Schatz D; Koeva-Balabanova J; Jonsson B
Biomed Hub; 2020; 5(2):15-67. PubMed ID: 32775335
[TBL] [Abstract][Full Text] [Related]
16. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
[TBL] [Abstract][Full Text] [Related]
17. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Front Public Health; 2016; 4():214. PubMed ID: 27747207
[TBL] [Abstract][Full Text] [Related]
18. Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group).
Aartsma-Rus A; Dooms M; Le Cam Y
Front Pharmacol; 2021; 12():744532. PubMed ID: 34975469
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
